VaxGen news from FierceVaccines
NewsVaxGen sells anthrax vaccine to its old rival
Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to Read more...
VaxGen faces possible liquidation after merger flops
The spectacularly unsuccessful VaxGen has called off an effort to Read more...
| Press ReleasesPRESS RELEASE: VaxGen Further Restructures; Reduces Workforce from 61 to 27 Employees VaxGen Further Restructures; Reduces Workforce from 61 to 27 Employees SOUTH SAN FRANCISCO, Calif., Sept. 13 -- VaxGen Inc. today announced further cost-cutting measures consistent with its Read more... |
Get more VaxGen coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight